Interestingly, the immunophenotype at relapse showed loss of the lymphoid markers Tdt, CD19, and CD22 and gain of MPO, thus corresponding to the immunophenotypic profile of an AML with minimal differentiation. This evidence concerns the gene CD19 and acute myeloid leukemia.